Vividion Therapeutics Inc., a biotechnology company that seeks to develop drugs for cancer and immune disorders using "traditionally undruggable targets," filed for an initial public offering. In its filing, the San Diego company said its technology "addresses the key limitations of conventional screening techniques and allows us to discover previously unknown, or cryptic, functional pockets on the surface of proteins and identify small molecules that selectively bind to thos

Tempest to Trade on Nasdaq Public Markets Under Ticker “TPST” SOUTH SAN FRANCISCO, Calif. and ANN ARBOR, Mich., June 22, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (“Tempest”), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, and Millendo Therapeutics, Inc. (Nasdaq: MLND) (“Millendo”), announced today the results for the proposals voted upon by Millendo stockholders at a Sp

SOUTH SAN FRANCISCO, Calif., June 16, 2021 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, today announced the pricing of its initial public offering of 25,000,000 shares of its common stock at a public offering price of $17.00 per share. All of the shares of common stock are being offered by Lyell. The gross proceeds from the offering, before deducting

Shares of MorphoSys AG ADR MOR, -12.90% were down 8.9% in premarket trading on Wednesday after the company announced a $1.7 billion acquisition of Constellation Pharmaceuticals Inc. CNST, 67.17%. Constellation's stock soared 61.3% in premarket trade. The boards of both companies have approved the deal, which is expected to close in the third quarter of 2021. Constellation, which is based in Cambridge, Mass., is developing a number of cancer and hematology therapies, all of wh